Integer Holdings (ITGR)
(Delayed Data from NYSE)
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Zacks News
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Masimo (MASI), UCHealth Unite to Improve Care With Telehealth
by Zacks Equity Research
Masimo (MASI) collaborates with UCHealth to boost patient care by combining its latest virtual care technologies with UCHealth's clinical expertise and telehealth innovations.
Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company???s transformational plans continue to benefit its operating income.
Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes
by Zacks Equity Research
Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.
GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility
by Zacks Equity Research
GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Boston Scientific (BSX) Completes First Case With Its PFA System
by Zacks Equity Research
Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
Is Elekta (EKTAY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
by Zacks Equity Research
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
Integer Holdings (ITGR) Q4 Earnings and Sales Beat, Margins Up
by Zacks Equity Research
Integer Holdings (ITGR) reports fourth-quarter results, with earnings and revenues beating their respective consensus marks.
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval
by Zacks Equity Research
Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.
Veeva (VEEV) & Boehringer Partner to Boost Animal Healthcare
by Zacks Equity Research
Veeva (VEEV) collaborates with Boehringer to offer its Veeva Vault Clinical and Veeva Vault RIM applications to improve animals??? healthcare via technological upliftment.
Compared to Estimates, Integer (ITGR) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Integer (ITGR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards (EW) Gains From Balanced Core Growth and New Launches
by Zacks Equity Research
Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi
by Zacks Equity Research
Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like SUN, ITGR, DB and LRN are seeing price strength and have a high chance of carrying the momentum forward.
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
by Zacks Equity Research
Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.
Medical Products Stocks' Earnings Due on Feb 15: WST, ITGR & More
by Debanjana Dey
Medical Products companies' quarterly results are likely to reflect strength in customer demand. Let's see how ITGR, WST, AMN and PACB are placed ahead of their earnings releases.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
CVS Health (CVS) Gains From Digital Adoption Amid Competition
by Zacks Equity Research
CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.